Cognition Therapeutics is conducting the Phase 2 START Study.
1 report, 1 independent
Updated Sep 3
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Cognition Therapeutics is conducting the Phase 2 START Study.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
Cognition Therapeutics (United States)
company in Pittsburgh, United States
Nothing else this week.
-
Start
Nothing else this week.
Coverage
Newest first; wire copies grouped- GlobeNewswireCognition Therapeutics Study of Zervimesine (CT1812) in Early Alzheimer’s Disease Reaches 75% Enrollment Target PURCHASE, N.Y., Sept. 03, 2025 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., (the C